1. Signaling Pathways
  2. Immunology/Inflammation
  3. Interleukin Related

Interleukin Related

IL

Interleukins are a group of cytokines (secreted proteins and signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. They promote the development and differentiation of T and B lymphocytes, and hematopoietic cells. Interleukin receptors on astrocytes in the hippocampus are also known to be involved in the development of spatial memories in mice.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P3912
    Endotoxin inhibitor
    Endotoxin inhibitor a synthetic peptide that binds lipid A with high affinity, thereby detoxifying LPS (HY-D1056) and preventing LPS-induced cytokine release in vivo. Endotoxin inhibitor inhibits the febrile response to LPS with very low toxicity and lethality.
    Endotoxin inhibitor
  • HY-N8444
    Triptoquinone A
    Inhibitor
    Triptoquinone A, an interleukin 1 inhibitor, inhibits endomycin (LPS) or interleukin (IL-1β)-promoted induction of nitric oxide synthase (NOS) in vascular smooth muscle, thereby inhibiting Arg-induced vascular relaxation.
    Triptoquinone A
  • HY-P11093
    Papiliocin
    Inhibitor
    Papiliocin is a potent peptide antibiotic with both anti-inflammatory and antibacterial activities. Papiliocin is primarily active against Gram-negative bacteria. Papiliocin exhibits strong anti-inflammatory activity against cell, exerting its anti-inflammatory activity by inhibiting the production of NO and the secretion of TNF-α and MIP-2. Papiliocin participates in the innate defense response mechanism by inhibiting the Toll-like receptor pathway and NF-κB. Papiliocin induces apoptosis in fungal cells and increases the total level of intracellular ROS. Papiliocin acts as an effective antiseptic peptide in sepsis models. Papiliocin is useful in anti-inflammatory and antibacterial research.
    Papiliocin
  • HY-162844
    CDN-3
    CDN-3 (Compound 10) is a cyclic dideoxy nucleotide derivative. CDN-3 can stimulate the production of IFN-β, activate the IRF-3 and NF-κB pathways, and induce the production of type I interferons as well as pro-inflammatory factors such as IL-6 and TNF-α. CDN-3 can inhibit cancer cells proliferation. CDN-3 can be used for research of colon cancer.
    CDN-3
  • HY-N19816
    7-O-Methyl glabranin
    Inhibitor
    7-O-Methyl glabranin is a flavonoid compound and also an inhibitor of LPS-induced TNF-α and IL-1β production. 7-O-Methyl glabranin can be used in the research of diseases such as inflammation.
    7-O-Methyl glabranin
  • HY-182777
    HDAC6-IN-80
    Inhibitor
    HDAC6-IN-80 is an orally active, selective HDAC6 inhibitor with an IC50 of 8.5 nM. HDAC6-IN-80 inhibits lipopolysaccharide-induced microglial activation, reduces the levels of iNOS, COX-2, TNF-α and IL-6, and alleviates sensory hypersensitivity behaviors. HDAC6-IN-80 can be used for the research of inflammatory pain and chemotherapy-induced peripheral neuropathy.
    HDAC6-IN-80
  • HY-P991515
    TQH-2722
    Inhibitor
    TQH-2722 is a humanized IgG4 anti-IL-4Rα monoclonal antibody. TQH-2722 targets the IL-4Rα receptor in humans, effectively disrupting the interaction between IL-4Rα and the downstream cytokines IL-4 and IL-13, thereby inhibiting inflammatory response. TQH-2722 can be used for the study of atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP).
    TQH-2722
  • HY-186103
    Glycolipid C34
    Glycolipid C34, α-GalCer (HY-102022) analog, is a CD1d-binding glycolipid antinfection agent. Glycolipid C34 mediates invariant natural killer T cell activation and increases the secretion of IFN-γ and IL-4. Glycolipid C34 promotes clearance of bacterial infections in murine models and enhances protective immunity against viral infections. Glycolipid C34 can be used for the research of bacterial infection, viral infection.
    Glycolipid C34
  • HY-169420
    IL-6-IN-1
    Inhibitor
    IL-6-IN-1 (Compound 22) inhibits the release of IL-6 with an IC50 of 1.065 μM. IL-6-IN-1 exhibits anti-inflammatory efficacy in LPS (HY-D1056)-induced acute lung injury in mouse model.
    IL-6-IN-1
  • HY-134371
    IL-17 modulator 2
    Modulator
    IL-17 modulator 2 (compound 159) is an orally active modulator of IL-17. IL-17 modulator 2 significantly reduces IL-6, IFN-γ, and edema. IL-17 modulator 2 can used in study arthritis.
    IL-17 modulator 2
  • HY-159902
    KRN7000 analog 3
    Activator
    KRN7000 analog 3 (Compound 14),α-GalCer (HY-102022) analogue, is a iNKT agonist. KRN7000 analog 3 induces higher levels of IL-2 cytokine secretion (49.2-62.6 ng/mL) than a-GalCer (44.1 ng/mL) in mNK1.2 cells. KRN7000 analog 3 is promising for research of antitumor agents and vaccine adjuvants.
    KRN7000 analog 3
  • HY-175833
    NF-κB-IN-20
    Inhibitor
    NF-κB-IN-20 is an orally active NF-κB inhibitor. NF-κB-IN-20 directly binds to the Keap1 protein, activating the Keap1/Nrf2/HO-1 antioxidant pathway, and simultaneously inhibiting the NF-κB inflammatory pathway, thereby synergistically reducing oxidative stress and inflammatory responses. NF-κB-IN-20 M11 inhibits the expression of IL-6, IL-1β, and TNF-α, significantly reduces the level of ROS, and restores the mitochondrial membrane potential. NF-κB-IN-20 can be used for the study of acute lung injury (ALI).
    NF-κB-IN-20
  • HY-181474
    CF-Vanillin
    Inhibitor
    CF-Vanillin is an orally active hypolipidemic/hepatic protector with strong binding affinity for PPAR-α. CF-Vanillin exerts antioxidant and anti-inflammatory effects by activating the Nrf2/HO-1 signaling pathway. CF-Vanillin reduces triglyceride and total cholesterol levels and alleviates liver injury. CF-Vanillin can be used in the research of diseases such as hyperlipidemia and liver injury.
    CF-Vanillin
  • HY-175007
    RIPK1-IN-32
    Inhibitor
    RIPK1-IN-32 is a RIPK inhibitor with anti-inflammatory activity. RIPK1-IN-32 inhibits nitric oxide (NO) release with an IC50 of 3.26 μM. RIPK1-IN-32 significantly alleviates acute liver injury associated with sepsis through the RIPK1/NF-κB/MAPK pathway, therefore preventing the nuclear translocation of p65 and c-fos, which results in reduced expression of TNF-α and IL-6. RIPK1-IN-32 can be used for the study of acute liver injury and sepsis.
    RIPK1-IN-32
  • HY-125864D
    Rabbit Fibrinogen
    Inducer
    Rabbit Fibrinogen is a native fibrinogen from rabbit plasma. Fibrinogen is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases.
    Rabbit Fibrinogen
  • HY-P991275
    CNTO4088
    Inhibitor
    CNTO4088 is a monoclonal antibody inhibitor targeting interleukin-23 (IL-23). CNTO4088 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis.
    CNTO4088
  • HY-181822
    BMS-986331
    Activator
    BMS-986331 is an orally active selective N-Formyl Peptide Receptor 2 (FPR2) agonist with an EC50 of 0.5 nM in humans and 1 nM in rats. BMS-986331 activates Gαi2, GαoA, Gα12, Gα13 signaling pathways, recruits β-arrestin1 and β-arrestin2, and inhibits downstream cAMP. BMS-986331 induces the expression and release of the pro-resolution cytokine IL-10. BMS-986331 improves cardiac structure and function in a rat model of heart failure induced by permanent coronary artery occlusion. BMS-986331 can be used for the research of heart failure.
    BMS-986331
  • HY-119514
    BC12
    Inhibitor
    BC12 is a barbituric acid derivative and a phosphodiesterase 7 (PDE7) inhibitor, with an IC50 of 0.77 μM against human targets. BC12 inhibits the enzymatic activity of PDE7, but this activity is not the driver of its immunomodulatory effects on T lymphocytes. BC12 blocks the upregulation of IL-2 transcription in activated T cells. BC12 modulates the transcriptional response of T cells upon stimulation, exerting anti-inflammatory and pro-stress effects. BC12 inhibits the proliferation of primary mouse T cells and the IL-2 secretion of human peripheral blood T lymphocytes. BC12 exerts immunosuppressive and immunomodulatory effects on T lymphocyte function. BC12 can be used in research related to T lymphocyte-mediated diseases.
    BC12
  • HY-N15307
    Trigraecum
    Inhibitor
    Trigraecum is a flavonoid compound found in Dracaena steudneri and Dalbergia cochinchinensis, exhibiting anti-inflammatory activity. It can inhibit the LPS (HY-D1056)-induced production of IL-1β, IL-2, GM-CSF, and TNF-α in human peripheral blood mononuclear cells. Trigraecum holds promise for research on inflammatory diseases.
    Trigraecum
  • HY-102084R
    LMT-28 (Standard)
    Inhibitor
    LMT-28 (Standard) is the analytical standard of LMT-28 (HY-102084). This product is intended for research and analytical applications. LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130.
    LMT-28 (Standard)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.